<DOC>
	<DOCNO>NCT00881166</DOCNO>
	<brief_summary>Adult subject malignant disease appropriate treatment carboplatin/paclitaxel , carboplatin/etoposide , topotecan , docetaxel erlotinib accord standard dose regimen enrol treatment arm . Primary objective : Determine MTD . Secondary objective : Response rate , PK , quantify MP-470 PK SOC , collect pharmacodynamic information . Evaluate overall safety MP-470 co-administered specific SOC treatment .</brief_summary>
	<brief_title>Safety MP470 Combination With Standard-of-Care Chemotherapy Regimens Treat Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Malignant disease appropriate initiating treatment carboplatin/paclitaxel , carboplatin/etoposide , topotecan , docetaxel , erlotinib . 2 . Must able read , understand , sign IRB approve Informed Consent Form . 3 . At least 18 year old . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 5 . Adequate bone marrow function ; normal renal hepatic function , normal cardiac function . 1 . Any active invasive malignancy except nonmelanoma skin cancer cervical carcinoma situ . 2 . History significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure and/or myocardial infarction . 3 . Received anticancer agent ( ) within past 3 week , include investigational agent , chemotherapy ( 6 week nitrosoureas mitomycin ) , immunotherapy , biologic hormonal therapy LHRH agonist . 4 . Received prior radiation therapy within past 4 week . 5 . Any serious , uncontrolled active infection require systemic treatment know infection HIV , HCV HBV . 6 . Patient require treatment immunosuppressive agent corticosteroid appropriate SOC chemotherapy regimen stable dos least 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>MP-470</keyword>
	<keyword>Multi-targeted Tyrosine Kinase Inhibitor</keyword>
	<keyword>Malignant disease</keyword>
</DOC>